sacituzumab tirumotecan   Click here for help

GtoPdb Ligand ID: 13791

Synonyms: Jiataile® | MK-2870 | sac-TMT | SKB264
Approved drug
sacituzumab tirumotecan is an approved drug
Compound class: Antibody
Comment: Sacituzumab tirumotecan (SKB264/MK-2870) is an antibody-drug conjugate (ADC) [1]. It is the same humanized anti-TROP-2 monoclonal antibody as the previously approved ADC sacituzumab govitecan, but carrying a different topoisomerase inhibitor payload (tirumotecan/KL610023) that is a belotecan-derivative. TROP-2 is a transmembrane glycoprotein, cell surface antigen which has oncogenic activity in cancers of epithelial origin [2], but expression is restricted in normal tissue. Directing the topoisomerase inhibitor selectively to cancer cells via TROP-2 binding is predicted to limit toxicity towards healthy tissue/cells.
Click here for help
Bioactivity Comments
The intracellularly-cleaved toxic payload causes cell cycle arrest at the G2/S stage and death of TROP2 +ve cells. The anti-proliferative IC50 of tirumotecan/KL610023 in HCC1806 cells is 1.8 nM [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
tumor associated calcium signal transducer 2 Hs Antibody Binding 9.5 pKd - 1
pKd 9.5 (Kd 3.1x10-10 M) [1]
Description: Binding affinity determined by SPR